Durable response to tyrosine kinase inhibitor therapy in a lung cancer patient harboring epidermal growth factor receptor tandem kinase domain duplication

Journal of Thoracic Oncology

Volumn 10, Issue 10, 2015, Pages e97-e99

  Baik, Christina S ^a   Wu, David ^a   Smith, Christina ^a   Martins, Renato G ^a   Pritchard, Colin C ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; PACLITAXEL; PEMETREXED; EGFR PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER SURGERY; CASE REPORT; DISEASE COURSE; DRUG WITHDRAWAL; FEMALE; GENE DUPLICATION; GENE MUTATION; HUMAN; LOBECTOMY; LUNG ALVEOLUS CELL CARCINOMA; LUNG BIOPSY; LUNG INFILTRATE; MIDDLE AGED; NEXT GENERATION SEQUENCING; PRIORITY JOURNAL; TANDEM KINASE DOMAIN DUPLICATION; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; ENZYMOLOGY; LUNG NEOPLASMS; METABOLISM; PROTEIN TERTIARY STRUCTURE;

CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PROTEIN STRUCTURE, TERTIARY; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84942511240     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000586     Document Type: Article

References (6)

1. Pritchard CC, Salipante SJ, Koehler K, et al. Validation and implementation of targeted capture and sequencing for the detection of actionable mutation, copy number variation, and gene rearrangement in clinical cancer specimens. J Mol Diagn 2014;16:56-67.
2. Ozer BH, Wiepz GJ, Bertics PJ. Activity and cellular localization of an oncogenic glioblastoma multiforme-associated EGF receptor mutant possessing a duplicated kinase domain. Oncogene 2010;29: 855-864.
3. Furgason JM, Li W, Milholland B, et al. Whole genome sequencing of glioblastoma multiforme identifes multiple structural variations involved in EGFR activation. Mutagenesis 2014;29:341-350.
4. Garassino MC, Martelli O, Broggini M, et al; TAILOR Trialists. Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol 2013;14:981-988.
5. Kawaguchi T, Ando M, Asami K, et al. Randomized phase III trial of erlotinib versus docetaxel as second-or third-line therapy in patients with advanced non-small-cell lung cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA). J Clin Oncol 2014;32:1902-1908.
6. Bell DW, Lynch TJ, Haserlat SM, et al. Epidermal growth factor receptor mutations and gene amplifcation in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT geftinib trials. J Clin Oncol 2005;23:8081-8092.